RxDoctor Payments Data

Hisham Kashou, MD

Cardiovascular Disease · Johnson City, NYNPI 1710988266

Payments from drug & device makers

$155,797in general payments, 2019–2025

Across 721 payments — averaging $216.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$79K
  • AstraZeneca$26K
  • E.r. Squibb & Sons, L.L.C.$21K
  • Pfizer$9K
  • Boehringer Ingelheim$5K
  • Edwards Lifesciences$3K
  • plus $11K from 40 others

What the payments were for

  • Consulting fees$2,0403%
  • Speaking & faculty fees$55,18568%
  • Travel & lodging$2,4803%
  • Food & beverage$20,88526%
  • Education$160%
  • Entertainment$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$155,797 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$199,449
Medicare patients
1,553
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan36$59,859
EliquisApixaban33$53,794
FarxigaDapagliflozin Propanediol16$26,318
Metoprolol Succinate142$2,194
Atorvastatin Calcium161$1,783
ClopidogrelClopidogrel Bisulfate92$1,287
Carvedilol96$965
Isosorbide Mononitrate ErIsosorbide Mononitrate56$676
Ramipril48$563
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$469
Rosuvastatin Calcium28$467
Warfarin Sodium29$368
Digoxin11$367
Nitroglycerin30$360
Ezetimibe13$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$78,869$59,85936 claims
PfizerEliquis$9,141$53,79433 claims
AstraZenecaFarxiga$26,433$26,31816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →